OBJECTIVE: To reach a consensus about contralateral prophylactic mastectomy in unilateral breast cancer. SUMMARY BACKGROUND DATA: There has been a substantial increase in the number of North American women with unilateral breast cancer undergoing a therapeutic mastectomy and a contralateral prophylactic mastectomy (CPM) either simultaneously or sequentially. The purpose of this project was to create a nationally endorsed consensus statement for CPM in women with unilateral breast cancer using modified Delphi consensus methodology. METHODS: A nationally representative expert panel of 19 general surgeons, 2 plastic surgeons, 2 medical oncologists, 2 radiation oncologists, and 1 psychologist was invited to participate in the generation of a consensus statement. Thirty-nine statements were created in 5 topic domains: predisposing risk factors for breast cancer, tumor factors, reconstruction/symmetry issues, patient factors, and miscellaneous factors. Panelists were asked to rate statements on a 7-point Likert scale. Two electronic rounds of iterative rating and feedback were anonymously completed, followed by an in-person meeting. Consensus was reached when there was at least 80% agreement. RESULTS: Our panelists did not recommend for average risk women with unilateral breast cancer. The panel recommended CPM for women with a unilateral breast cancer and previous Mantle field radiation or a BrCa1/2 gene mutation. The panel agreed that CPM could be considered by the surgeon on an individual basis for: women with unilateral breast cancer and a genetic mutation in the CHEK2/PTEN/p53/PALB2/CDH1 gene, and in women who may have significant difficulty achieving symmetry after unilateral mastectomy. CONCLUSION: Contralateral prophylactic mastectomy is rarely recommended for women with unilateral breast cancer.
OBJECTIVE: To reach a consensus about contralateral prophylactic mastectomy in unilateral breast cancer. SUMMARY BACKGROUND DATA: There has been a substantial increase in the number of North American women with unilateral breast cancer undergoing a therapeutic mastectomy and a contralateral prophylactic mastectomy (CPM) either simultaneously or sequentially. The purpose of this project was to create a nationally endorsed consensus statement for CPM in women with unilateral breast cancer using modified Delphi consensus methodology. METHODS: A nationally representative expert panel of 19 general surgeons, 2 plastic surgeons, 2 medical oncologists, 2 radiation oncologists, and 1 psychologist was invited to participate in the generation of a consensus statement. Thirty-nine statements were created in 5 topic domains: predisposing risk factors for breast cancer, tumor factors, reconstruction/symmetry issues, patient factors, and miscellaneous factors. Panelists were asked to rate statements on a 7-point Likert scale. Two electronic rounds of iterative rating and feedback were anonymously completed, followed by an in-person meeting. Consensus was reached when there was at least 80% agreement. RESULTS: Our panelists did not recommend for average risk women with unilateral breast cancer. The panel recommended CPM for women with a unilateral breast cancer and previous Mantle field radiation or a BrCa1/2 gene mutation. The panel agreed that CPM could be considered by the surgeon on an individual basis for: women with unilateral breast cancer and a genetic mutation in the CHEK2/PTEN/p53/PALB2/CDH1 gene, and in women who may have significant difficulty achieving symmetry after unilateral mastectomy. CONCLUSION: Contralateral prophylactic mastectomy is rarely recommended for women with unilateral breast cancer.
Authors: J E Squires; D Stacey; M Coughlin; M Greenough; A Roberts; K Dorrance; M Clemons; J M Caudrelier; I D Graham; J Zhang; M Demery Varin; A Arnaout Journal: Curr Oncol Date: 2019-04-01 Impact factor: 3.677
Authors: Catherine Pesce; Jennifer Jaffe; Kristine Kuchta; Katharine Yao; Mark Sisco Journal: Breast Cancer Res Treat Date: 2020-10-08 Impact factor: 4.872
Authors: David W Lim; Helene Retrouvey; Isabel Kerrebijn; Kate Butler; Anne C O'Neill; Tulin D Cil; Toni Zhong; Stefan O P Hofer; David R McCready; Kelly A Metcalfe Journal: Ann Surg Oncol Date: 2021-04-05 Impact factor: 5.344
Authors: Mary C Schroeder; Yu-Yu Tien; Lillian M Erdahl; Ingrid M Lizarraga; Brahmendra R Viyyuri; Sonia L Sugg Journal: Surgery Date: 2020-08-18 Impact factor: 3.982
Authors: J E Squires; S N Simard; S Asad; D Stacey; I D Graham; M Coughlin; M Clemons; J M Grimshaw; J Zhang; J M Caudrelier; A Arnaout Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677
Authors: M L Quan; I A Olivotto; N N Baxter; C M Friedenreich; K Metcalfe; E Warner; K MacLennan; J E Stephen; M R Akbari; D Howell; S Narod Journal: Curr Oncol Date: 2020-10-01 Impact factor: 3.677
Authors: Patricia A Parker; Susan K Peterson; Yu Shen; Isabelle Bedrosian; Dalliah M Black; Alastair M Thompson; Jonathan C Nelson; Sarah M DeSnyder; Robert L Cook; Kelly K Hunt; Robert J Volk; Scott B Cantor; Wenli Dong; Abenaa M Brewster Journal: J Clin Oncol Date: 2018-07-25 Impact factor: 44.544
Authors: Ingrid M Lizarraga; Mary C Schroeder; Ismail Jatoi; Sonia L Sugg; Amy Trentham-Dietz; Laurel Hoeth; Elizabeth A Chrischilles Journal: Ann Surg Oncol Date: 2021-07-12 Impact factor: 5.344